论文部分内容阅读
艾伯替丁(Ebrotidine)是继西米替丁(Cimetidine)、雷尼替丁(Ranitidine)、尼扎替丁(Nizatidine)之后发现的第一个具有胃保护作用的新一代H_2—受体拮抗剂。它的胃保护作用、抗幽门螺旋杆菌作用,吸烟溃疡患者更易使用以及严重副反应发生率低等特点,使其成为有别于其他H_2—受体拮抗剂的新药。目前,Ebrotidine被认为是治疗由非甾体抗炎药、酒精、幽门螺旋杆菌及其他刺激引起的胃及十二指肠溃疡、侵蚀性返流食管炎等急性胃损伤的理想药物。
Ebrotidine is the first new generation of H 2 -receptor antagonist with gastric protective effect discovered after Cimetidine, Ranitidine and Nizatidine Agent. Its stomach protection, anti-H pylori action, ease of use in patients with smoking ulcers and the low incidence of serious side effects make it a new drug that is distinct from other H 2 -receptor antagonists. Ebrotidine is currently considered as the ideal drug for the treatment of acute gastric lesions such as stomach and duodenal ulcer, aggressive reflux esophagitis caused by NSAIDs, alcohol, H. pylori and other stimuli.